Please enable JavaScript.

Coggle requires JavaScript to display documents.

called Novel drug due to therapeutic indication - Coggle Diagram

- - - - This activity outlines the indications, mechanism of action, safe administration, adverse effects, contraindications, monitoring, over-dose management, and toxicity of apixaban
        
        highlights the role of inter professional team members in patient care using apixaban as a treatment option.
      - Uses safety with Cronic Kidney Disease as less bleeding ( Miho Kimochi -2017)
        
        BMI of at least 40kg\m2 to benefit from more convenient , and possible safer anticoagulant ( Margarita Kushnir 2019)
  - - - intrinsic pathway
      - extrinsic pathways( tissue )
  - - - 2-have a predictable anticoagulant effect and less SE
        
        4 -more convenient for patient and health care provider
        
        more safety tolerability , treat VTE with individual cancer it lower the extremities venous thrombosis and PE increase life expectancy and improve quality of life live longer without worries about regular laboratory test or to forbitten to special food their is no food interaction 2020
        
        5-lower risk of drug interaction and less toxicity
        
        Relative risk ratio
        
        drug delivery not administration come as oral and parenteral
        
        has lower potential for drug interaction to warfarin
        
        does not interact with vit -k containing food
        
        Eliquis is available in a fixed -dose tablet form ,no need with other anticoagulant drug
        
        no need for calculation \ adjustment
        
        no need for dietary restriction
        
        quick onset of action action
        
        24 hour
        
        warfarin takes 3-4 days
        
        not require regular monitoring of blood clotting parameter as INR
        
        this eliminate the need for frequent dose adjustment
        
        reduce the risk of complication with improper dose
      - 2
      - 3- novel effect works effectively and more safe in preventing stroke and systemic embolism in patient with non - valvular AF
        
        and in treating and preventing DVT and PE
        
        lower risk of bleeding
- - - - It is approved for the treatment of pulmonary embolism (PE)
        
        It is also indicated for the prophylaxis in DVT, which may lead to PE, in patients who may have undergone knee or hip replacement surgery
        
        It is also approved for reducing the risk of recurrent DVT and PE after initial therapy
  - - - they are available in oral formula
      - do not require drug monitoring
      - other s anticoagulant need either IV access \SC inj or venipuncture to monitor drug concentration